Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1026

Sort by

Sort Order Select

Journal Articles

Androgen receptor signaling as a new target for intervention in acute myeloid leukemia

Fenghua Qian, Deborpita Sarkar, Brooke E. Arner, Vanessa M. Peduzzi, Yuting Bai, Baiye Ruan, Bei Jia, Hong Zheng, Robert F. Paulson, K. Sandeep Prabhu

Blood Adv (2025) 9 (24): 6326–6339.

https://doi.org/10.1182/bloodadvances.2024012639

Published: 2025

Includes: Supplemental data

Journal Articles

Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies

Blood Adv (2025) 9 (24): 6314–6325.

https://doi.org/10.1182/bloodadvances.2025017084

Published: 2025

Includes: Supplemental data

Journal Articles

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL

Malte Roerden, Luca Hensen, Britta Besemer, Friederike Schwartz, Kristina Reuss, Alisha Weiss-Haug, Lennart Harland, Franziska Ginsberg, Christoph Faul, Wolfgang Bethge, Claudia Lengerke

Blood Adv (2025) 9 (24): 6340–6344.

https://doi.org/10.1182/bloodadvances.2025017770

Published: 2025

Journal Articles

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML

Blood Adv (2025) 9 (24): 6455–6466.

https://doi.org/10.1182/bloodadvances.2025017244

Published: 2025

Includes: Supplemental data

Journal Articles

Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration

Xiaoyan Liu, Jinxian Wu, Xinqi Li, Ruiyang Pan, Li Liu, Tingting Huang, Linlu Ma, Guopeng Chen, Qian Wang, Nan Zhang, Xiqin Tong, Yuxin Tan, Hongqiang Jiang, Yuxing Liang, Min Shen, Ruihang Li, Wanyue Yin, Xian Zhang, Fuling Zhou

Blood Adv (2025) 9 (24): 6575–6589.

https://doi.org/10.1182/bloodadvances.2024015762

Published: 2025

Includes: Supplemental data

Journal Articles

Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis

Abdulrahman Alhajahjeh, Naira Link Woite, Benjamin Rolles, Jessica M. Stempel, Alain Mina, Lourdes Mendez, Tariq Kewan, Nikolai A. Podoltsev, Maximilian Stahl, Alyssa A. Grimshaw, Amer M. Zeidan, Jan Philipp Bewersdorf

Blood Adv (2025) 9 (24): 6511–6523.

https://doi.org/10.1182/bloodadvances.2025017611

Published: 2025

Includes: Supplemental data

Journal Articles

Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways

Tiziano Barbui, Joseph Michael Scandura

Blood Adv bloodadvances.2025018011.

https://doi.org/10.1182/bloodadvances.2025018011

Published: 2025

Includes: Supplemental data

Journal Articles

Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress

Christina Mayerhofer, Eve Crompton, Ernst Mayerhofer, Trine A. Kristiansen, Tsuyoshi Fukushima, Samuel Keyes, Azeem Sharda, Dan Li, Carmen Da Silva, Deumaya Shrestha, Anna Kiem, Tobias Feuchtinger, David T Scadden, Peter Grant Miller

Blood Adv bloodadvances.2025016618.

https://doi.org/10.1182/bloodadvances.2025016618

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure

Kuo-Kai Chin, Brian J. Ball, Yasmin Abaza, Jessica K Altman, Rahul K Thakur, Moiez Ali, Andriy Derkach, Mark B. Geyer, Aaron D. Goldberg, Tamanna Haque, Meghan C. Thompson, Jae H Park, Martin S. Tallman, Sheng F. Cai, Eunice S. Wang, Ibrahim Aldoss, Eytan M. Stein

Blood Adv bloodadvances.2025018178.

https://doi.org/10.1182/bloodadvances.2025018178

Published: 2025

Includes: Supplemental data

Journal Articles

Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway

Yanan Chen, Koon Chuen Chan, Chun Fung Sin, Lichuan Zheng, Dandan Wang, Lingge Tu, Fangfang He, Wan Hei Jeffrey Hui, Hoi Ki Leung, Leslie Kar Fai Chan, Sze Pui Tsui, Hoi-yi Chan, Alvin Chun Hang Ma, Anskar YH Leung, Xuan Sun

Blood Adv bloodadvances.2025017005.

https://doi.org/10.1182/bloodadvances.2025017005

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi, Felicetto Ferrara, Paola Minetto, Maria Paola Martelli, Carola Riva, Patrizia Chiusolo, Michela Rondoni, Saveria Capria, Clara Minotti, Federica Pilo, Salvatore Perrone, Andrea Corbingi, Francesco Grimaldi, Giulia De Luca, Carla Fili, Caterina Alati, Francesco Mannelli, Federica Lessi, Francesco Marchesi, Lorenzo Brunetti, Debora Capelli, Anna Lina Piccioni, Calogero Vetro, Fanny Erika Palumbo, Carla Mazzone, Alessandra Sperotto, Giovanni Luzi, Michelina Dargenio, Sabrina Mariani, Marco Cerrano, Antonino Mulè, Ambra Di Veroli, Elisa Meddi, Federico Moretti, Cristina Papayannidis, Alessandro Isidori, Antonella Ferrari, Sara Galimberti, Daniela Cilloni, Massimo Breccia, Francesco Lanza, Michele Gottardi, Roberto Cairoli, Anna Candoni, Livio Pagano, Elisabetta Todisco, Roberto Massimo Lemoli, Adriano Venditti, Francesco Buccisano

Blood Adv bloodadvances.2025017089.

https://doi.org/10.1182/bloodadvances.2025017089

Published: 2025

Includes: Supplemental data

Journal Articles

The lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility

Kaifee Arman, Julie Ross, Eva-Maria Piskor, Luca Lazzari, Virginie Calderon, Gaspard Reulet, Maria Vera, Edlie St-Hilaire, Hugo Wurtele, Brian T. Wilhelm, Tarik Möröy

Blood Adv (2025) 9 (23): 6158–6174.

https://doi.org/10.1182/bloodadvances.2024015427

Published: 2025

Includes: Supplemental data

Journal Articles

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms

Isabella Diana Davidsen, Morten Kranker Larsen, Lea Löffler, Vibe Skov, Lasse Kjær, Trine Alma Knudsen, Anders Lindholm Sørensen, Sarah Friis Christensen, Sabrina Cordua, Christina Schjellerup Eickhardt-Dalbøge, Marie Hvelplund Kristiansen, Christina Ellervik, Troels Wienecke, Hans Carl Hasselbalch

Blood Adv (2025) 9 (23): 6189–6198.

https://doi.org/10.1182/bloodadvances.2025017016

Published: 2025

Includes: Supplemental data

Journal Articles

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

Blood Adv (2025) 9 (23): 6047–6058.

https://doi.org/10.1182/bloodadvances.2025017011

Published: 2025

Includes: Supplemental data

Journal Articles

Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes

Blood Adv (2025) 9 (23): 5988–6000.

https://doi.org/10.1182/bloodadvances.2025016608

Published: 2025

Includes: Supplemental data

Journal Articles

American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Blood Adv bloodadvances.2025017934.

https://doi.org/10.1182/bloodadvances.2025017934

Published: 2025

Includes: Supplemental data

Journal Articles

Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions

Liam MacPhee, Arefeh Rouhi, Ly P. Vu, Florian Kuchenbauer

Blood Adv (2025) 9 (22): 5937–5944.

https://doi.org/10.1182/bloodadvances.2024015611

Published: 2025

Journal Articles

Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia

Jan Schröder, Friederike Schwartz, Judith Metzdorf, Nick Barensteiner, Lucas Mix, Lisa-Marie Necke, Adrian Fehn, Andreas Riedel, Liv Jentzsch, Philipp Faustmann, Wichard Vogel, Wolfgang Andreas Bethge, Thomas Schroeder, Claudia Lengerke

Blood Adv bloodadvances.2025017908.

https://doi.org/10.1182/bloodadvances.2025017908

Published: 2025

Includes: Supplemental data

Journal Articles

Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation

Elisa A. Aquilanti, Lauren Kageler, Vincent Bozinov, Matthew L. Meyerson

Blood Adv bloodadvances.2025018090.

https://doi.org/10.1182/bloodadvances.2025018090

Published: 2025

Includes: Supplemental data

Journal Articles

TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells

Michael E. Lawler, Jennifer S. Romer-Seibert, Michael S. Bowman, Ramkrishna Mitra, Christine M. Eischen, Robert L. Bowman, Sara E. Meyer

Blood Adv (2025) 9 (22): 5888–5901.

https://doi.org/10.1182/bloodadvances.2025017018

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Androgen receptor signaling as a new target for intervention in acute myeloid leukemia

Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML

Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration

Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis

Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways

Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure

Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

The lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes

American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions

Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia

Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation

TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only